7 results

  • celecoxib

    (CELECOXIB)
    Quallent Pharmaceuticals Health LLC
    Celecoxib is indicated for managing signs and symptoms of osteoarthritis (OA), rheumatoid arthritis (RA), juvenile rheumatoid arthritis (JRA) in patients aged 2 and older, ankylosing spondylitis (AS), acute pain in adults, and primary dysmenorrhea.

  • citalopram

    (Citalopram Hydrobromide)
    QUALLENT PHARMACEUTICALS HEALTH LLC
    Citalopram tablets are indicated for the treatment of major depressive disorder (MDD) in adults.

  • lansoprazole

    (Lansoprazole)
    Quallent Pharmaceuticals Health LLC
    Lansoprazole delayed-release capsules are indicated for the short-term treatment of active duodenal ulcers, gastric ulcers, GERD, and erosive esophagitis, and for the eradication of H. pylori. They also help maintain healed ulcers and manage hypersecretory conditions like Zollinger-Ellison syndrome.

  • omeprazole

    (Omeprazole)
    Quallent Pharmaceuticals Health LLC
    Omeprazole delayed-release capsules are indicated for the short-term treatment of active duodenal and benign gastric ulcers, GERD symptoms, erosive esophagitis due to GERD, and for the long-term management of pathological hypersecretory conditions. It also aids in eradicating *H. pylori* to reduce ulcer recurrence.

  • quetiapine fumarate

    (quetiapine fumarate)
    Quallent Pharmaceuticals Health LLC
    Quetiapine is indicated for the treatment of schizophrenia, acute manic and depressive episodes associated with bipolar I disorder, and for maintenance treatment of bipolar I disorder as an adjunct. Efficacy in pediatric patients and for certain maintenance treatments has not been fully established in clinical trials.

  • topiramate

    (topiramate)
    Quallent Pharmaceuticals Health LLC
    Topiramate tablets are indicated for initial monotherapy and adjunctive therapy in treating partial-onset and primary generalized tonic-clonic seizures in patients aged 2 and older, as well as for seizure control in Lennox-Gastaut syndrome. Additionally, it is used for preventive migraine treatment in individuals aged 12 and older.

  • ustekinumab-ttwe

    (ustekinumab-ttwe)
    Quallent Pharmaceuticals Health LLC
    Ustekinumab-ttwe is indicated for treating moderate to severe plaque psoriasis in patients 6 years and older, active psoriatic arthritis in patients 6 years and older, and moderately to severely active Crohn's disease and ulcerative colitis in adults.